S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.83 (+0.36%)
AAPL   460.04 (+1.77%)
MSFT   208.70 (-0.23%)
FB   261.30 (+0.54%)
GOOGL   1,518.00 (+0.71%)
AMZN   3,161.02 (-0.04%)
NVDA   457.88 (+0.06%)
CGC   17.34 (+0.52%)
BABA   253.61 (-0.62%)
TSLA   1,621.00 (+4.26%)
GE   6.60 (-1.79%)
MU   46.14 (-4.83%)
AMD   81.84 (-0.93%)
T   29.91 (-0.89%)
F   7.03 (-1.13%)
ACB   10.18 (+3.88%)
GILD   68.18 (-0.96%)
NFLX   481.33 (+1.23%)
DIS   130.97 (-0.62%)
BAC   26.35 (-1.42%)
BA   174.66 (-0.44%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.83 (+0.36%)
AAPL   460.04 (+1.77%)
MSFT   208.70 (-0.23%)
FB   261.30 (+0.54%)
GOOGL   1,518.00 (+0.71%)
AMZN   3,161.02 (-0.04%)
NVDA   457.88 (+0.06%)
CGC   17.34 (+0.52%)
BABA   253.61 (-0.62%)
TSLA   1,621.00 (+4.26%)
GE   6.60 (-1.79%)
MU   46.14 (-4.83%)
AMD   81.84 (-0.93%)
T   29.91 (-0.89%)
F   7.03 (-1.13%)
ACB   10.18 (+3.88%)
GILD   68.18 (-0.96%)
NFLX   481.33 (+1.23%)
DIS   130.97 (-0.62%)
BAC   26.35 (-1.42%)
BA   174.66 (-0.44%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.83 (+0.36%)
AAPL   460.04 (+1.77%)
MSFT   208.70 (-0.23%)
FB   261.30 (+0.54%)
GOOGL   1,518.00 (+0.71%)
AMZN   3,161.02 (-0.04%)
NVDA   457.88 (+0.06%)
CGC   17.34 (+0.52%)
BABA   253.61 (-0.62%)
TSLA   1,621.00 (+4.26%)
GE   6.60 (-1.79%)
MU   46.14 (-4.83%)
AMD   81.84 (-0.93%)
T   29.91 (-0.89%)
F   7.03 (-1.13%)
ACB   10.18 (+3.88%)
GILD   68.18 (-0.96%)
NFLX   481.33 (+1.23%)
DIS   130.97 (-0.62%)
BAC   26.35 (-1.42%)
BA   174.66 (-0.44%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.83 (+0.36%)
AAPL   460.04 (+1.77%)
MSFT   208.70 (-0.23%)
FB   261.30 (+0.54%)
GOOGL   1,518.00 (+0.71%)
AMZN   3,161.02 (-0.04%)
NVDA   457.88 (+0.06%)
CGC   17.34 (+0.52%)
BABA   253.61 (-0.62%)
TSLA   1,621.00 (+4.26%)
GE   6.60 (-1.79%)
MU   46.14 (-4.83%)
AMD   81.84 (-0.93%)
T   29.91 (-0.89%)
F   7.03 (-1.13%)
ACB   10.18 (+3.88%)
GILD   68.18 (-0.96%)
NFLX   481.33 (+1.23%)
DIS   130.97 (-0.62%)
BAC   26.35 (-1.42%)
BA   174.66 (-0.44%)
Log in

NASDAQ:APLSApellis Pharmaceuticals Stock Price, Forecast & News

$28.91
+0.59 (+2.08 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$28.01
Now: $28.91
$29.08
50-Day Range
$25.89
MA: $30.06
$33.65
52-Week Range
$16.85
Now: $28.91
$45.04
Volume26,367 shs
Average Volume1.16 million shs
Market Capitalization$2.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.09
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for intravenous administration in systemic indications. It has a risk-sharing collaboration agreement with SFJ Pharmaceuticals Group for the development of APL-2 in hematologic indications. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.
Read More
Apellis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.74 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APLS
CUSIPN/A
Phone617-977-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.07 per share

Profitability

Net Income$-304,710,000.00

Miscellaneous

Employees87
Market Cap$2.19 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$28.91
+0.59 (+2.08 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

How has Apellis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Apellis Pharmaceuticals' stock was trading at $27.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, APLS stock has increased by 6.2% and is now trading at $28.91.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Apellis Pharmaceuticals?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Apellis Pharmaceuticals
.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Apellis Pharmaceuticals
.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals Inc (NASDAQ:APLS) released its quarterly earnings data on Friday, July, 31st. The company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by $0.24.
View Apellis Pharmaceuticals' earnings history
.

What price target have analysts set for APLS?

15 analysts have issued 12-month price objectives for Apellis Pharmaceuticals' shares. Their forecasts range from $29.00 to $86.00. On average, they expect Apellis Pharmaceuticals' stock price to reach $50.92 in the next twelve months. This suggests a possible upside of 76.1% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals
.

Has Apellis Pharmaceuticals been receiving favorable news coverage?

Press coverage about APLS stock has been trending extremely negative this week, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of -4.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Apellis Pharmaceuticals
.

Are investors shorting Apellis Pharmaceuticals?

Apellis Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 6,670,000 shares, an increase of 22.4% from the December 31st total of 5,450,000 shares. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is currently 4.9 days. Approximately 12.6% of the company's shares are short sold.
View Apellis Pharmaceuticals' Short Interest
.

Who are some of Apellis Pharmaceuticals' key competitors?

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include Fate Therapeutics (FATE), AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Opko Health (OPK), Viking Therapeutics (VKTX), Amarin (AMRN), Axsome Therapeutics (AXSM), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA) and Aurinia Pharmaceuticals (AUPH).

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the following people:
  • Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 47)
  • Dr. Pascal Deschatelets, Co-Founder & COO (Age 49)
  • Mr. Timothy E. Sullivan, Chief Financial Officer (Age 48)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder and Exec. VP of Clinical Devel. & Medical Affairs (Age 45)
  • Mr. Ahmad Sadr, VP of Technical Operations

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (2.81%), Victory Capital Management Inc. (2.60%), Candriam Luxembourg S.C.A. (1.60%), FIL Ltd (1.30%), FMR LLC (0.66%) and Bank of Montreal Can (0.44%). Company insiders that own Apellis Pharmaceuticals stock include Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Morningside Venture Investment, Pascal Deschatelets and Timothy Eugene Sullivan.
View institutional ownership trends for Apellis Pharmaceuticals
.

Which institutional investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, FIL Ltd, State of Wisconsin Investment Board, Alps Advisors Inc., Strs Ohio, FMR LLC, UBS Group AG, and SG Americas Securities LLC. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Alec Machiels, Cedric Francois, Federico Grossi, and Pascal Deschatelets.
View insider buying and selling activity for Apellis Pharmaceuticals
.

Which institutional investors are buying Apellis Pharmaceuticals stock?

APLS stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Bank of Montreal Can, Victory Capital Management Inc., Rhenman & Partners Asset Management AB, Jennison Associates LLC, TD Asset Management Inc., Rafferty Asset Management LLC, and Swiss National Bank. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Morningside Venture Investment, and Timothy Eugene Sullivan.
View insider buying and selling activity for Apellis Pharmaceuticals
.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $28.91.

How big of a company is Apellis Pharmaceuticals?

Apellis Pharmaceuticals has a market capitalization of $2.19 billion. The company earns $-304,710,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is www.apellis.com.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at 617-977-5700 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.